Predicting Outcome of Cytoreduction in Advanced Ovarian Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18+
SponsorFondazione Policlinico Universitario Agostino Gemelli IRCCS
About this trial
PREDAtOOR is a pilot study and this study aims at improving the selection of the best treatment strategy for patients with advanced ovarian cancer by using Camera Vision (CV) to predict outcomes of cyto reduction at the time of Diagnostic laparoscopy.
Eligibility criteria
Qualifiers
Patients treated at Fondazione Policlinico Gemelli Hospital, Rome Italy, Trillium -Credit Valley Hospital, Mississauga, Ontario and Princess Margaret Cancer Centre, Toronto, Canada
Patients fit for cytoreductive surgery
Patients with a primary diagnosis of suspect Stage III-IV ovarian cancer
Patients selected for interval cytoreductive surgery after NACT
Disqualifiers
Patients with pre-operative Stage I-II disease confined to the pelvis
Patients unfit for surgery
Lack of information about patients' surgical outcomes and clinicopathological characteristics
LGSOC, Clear cell and mucinous, non-epithelial histologic subtypes (if available)
Trial design
Treatments tested in this trial
- Artificial Intelligence
Treatment groups
151 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov